| Literature DB >> 34861940 |
Dario Oliveira Passos1, Min Li2, Robert Craigie2, Dmitry Lyumkis3.
Abstract
The retroviral protein Integrase (IN) catalyzes concerted integration of viral DNA into host chromatin to establish a permanent infection in the target cell. We learned a great deal about the mechanism of catalytic integration through structure/function studies over the previous four decades of IN research. As one of three essential retroviral enzymes, IN has also been targeted by antiretroviral drugs to treat HIV-infected individuals. Inhibitors blocking the catalytic integration reaction are now state-of-the-art drugs within the antiretroviral therapy toolkit. HIV-1 IN also performs intriguing non-catalytic functions that are relevant to the late stages of the viral replication cycle, yet this aspect remains poorly understood. There are also novel allosteric inhibitors targeting non-enzymatic functions of IN that induce a block in the late stages of the viral replication cycle. In this chapter, we will discuss the function, structure, and inhibition of retroviral IN proteins, highlighting remaining challenges and outstanding questions.Entities:
Keywords: Antiretroviral therapy; Drug design; Enzyme; Hydrolase; Retrovirus
Mesh:
Substances:
Year: 2021 PMID: 34861940 PMCID: PMC8732146 DOI: 10.1016/bs.enz.2021.06.007
Source DB: PubMed Journal: Enzymes ISSN: 1874-6047